American Association for Cancer Research
21598290cd181220-sup-210474_2_supp_5431444_pp59my.xlsx (55.79 kB)

Supplementary Table S13 from Tissue-Specific Oncogenic Activity of KRASA146T

Download (55.79 kB)
posted on 2023-04-03, 21:42 authored by Emily J. Poulin, Asim K. Bera, Jia Lu, Yi-Jang Lin, Samantha Dale Strasser, Joao A. Paulo, Tannie Q. Huang, Carolina Morales, Wei Yan, Joshua Cook, Jonathan A. Nowak, Douglas K. Brubaker, Brian A. Joughin, Christian W. Johnson, Rebecca A. DeStefanis, Phaedra C. Ghazi, Sudershan Gondi, Thomas E. Wales, Roxana E. Iacob, Lana Bogdanova, Jessica J. Gierut, Yina Li, John R. Engen, Pedro A. Perez-Mancera, Benjamin S. Braun, Steven P. Gygi, Douglas A. Lauffenburger, Kenneth D. Westover, Kevin M. Haigis

GSEA analysis of spleens expressing WT or mutant K-Ras.



Cancer Research UK

Mark Foundation for Cancer Research

Department of Defense

Cancer Prevention and Research Institute of Texas

American Cancer Society

Landry Cancer Biology Consortium

National Science Foundation

Boehringer Ingelheim



KRAS is the most frequently mutated oncogene. The incidence of specific KRAS alleles varies between cancers from different sites, but it is unclear whether allelic selection results from biological selection for specific mutant KRAS proteins. We used a cross-disciplinary approach to compare KRASG12D, a common mutant form, and KRASA146T, a mutant that occurs only in selected cancers. Biochemical and structural studies demonstrated that KRASA146T exhibits a marked extension of switch 1 away from the protein body and nucleotide binding site, which activates KRAS by promoting a high rate of intrinsic and guanine nucleotide exchange factor–induced nucleotide exchange. Using mice genetically engineered to express either allele, we found that KRASG12D and KRASA146T exhibit distinct tissue-specific effects on homeostasis that mirror mutational frequencies in human cancers. These tissue-specific phenotypes result from allele-specific signaling properties, demonstrating that context-dependent variations in signaling downstream of different KRAS mutants drive the KRAS mutational pattern seen in cancer. Although epidemiologic and clinical studies have suggested allele-specific behaviors for KRAS, experimental evidence for allele-specific biological properties is limited. We combined structural biology, mass spectrometry, and mouse modeling to demonstrate that the selection for specific KRAS mutants in human cancers from different tissues is due to their distinct signaling properties.See related commentary by Hobbs and Der, p. 696.This article is highlighted in the In This Issue feature, p. 681

Usage metrics

    Cancer Discovery



    Ref. manager